Isothymusin

Isothymusin

SCHEMBL694063

COc1c(OC)c(O)c2c(=O)cc(-c3ccc(O)cc3)oc2c1O

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.87
MAPT P10636 7/20 0.73
POLB P06746 5/20 0.73
KDM4E B2RXH2 5/20 0.73
ALDH1A1 P00352 5/20 0.73
KMT2A Q03164 3/20 0.73
GAA P10253 3/20 0.73
RECQL P46063 2/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
MEN1 O00255 2/20 0.73
MAPK1 P28482 2/20 0.72
TDP1 Q9NUW8 2/20 0.69
INPPL1 O15357 1/20 0.69
ALPL P05186 1/20 0.69
ALPI P09923 1/20 0.69
ALPG P10696 1/20 0.69
PKM P14618 1/20 0.69
APEX1 P27695 1/20 0.69
BLM P54132 1/20 0.69
MCL1 Q07820 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isothymusin SCHEMBL31483965 1.00 PPARG (0.87) PPARGMAPTPOLBKDM4EALDH1A1
Xanthomicrol SCHEMBL6257160 0.93 PPARG (1.00) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL29974322 0.93 PPARG (0.81) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL27221221 0.93 PPARG (0.81) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL30683238 0.90 PPARG (0.85) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL2180082 0.90 PPARG (0.85) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL30213777 0.90 PPARG (0.90) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL29449516 0.90 ALDH1A1 (0.88) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL8160531 0.89 ALDH1A1 (0.82) PPARGMAPTPOLBKDM4EALDH1A1
SCHEMBL7554410 0.88 PPARG (0.81) PPARGMAPTPOLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160244-A1 METHODS AND COMPOSITIONS FOR ENHANCING COLLAGEN, PROTEOGLYCAN, AND GLUTATHIONE SYNTHESIS IN THE SKIN NIMNI MARCEL 2010-06-24 US claimed
US-20090053290-A1 TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN NUVIANCE, INC. 2009-02-26 US claimed
EP-1998742-A2 TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN Nuviance, INC. (US) 2008-12-10 EP claimed
WO-2007103555-A2 TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN NUVIANCE, INC. (US) 2007-09-13 WO claimed
US-20060067959-A1 Compositions and methods for treatment of solar damage NIMNI MARCEL 2006-03-30 US claimed
US-20060045926-A1 Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin NIMNI MARCEL 2006-03-02 US claimed
US-6576271-B2 Using plant extract BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2003-06-10 US claimed
US-11738084-B2 Compositions for transfection of biomolecules into cells SZATHMARY SUSAN (US) 2023-08-29 US disclosed
EP-2421952-B1 COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS GALEN BIO INC (US) 2016-03-30 EP disclosed
EP-2421952-A2 COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS Galen Bio, Inc. (US) 2012-02-29 EP disclosed
WO-2010123798-A2 COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS GALENBIO, INC. (US) 2010-10-28 WO disclosed
US-20100160244-A1 METHODS AND COMPOSITIONS FOR ENHANCING COLLAGEN, PROTEOGLYCAN, AND GLUTATHIONE SYNTHESIS IN THE SKIN NIMNI MARCEL 2010-06-24 US disclosed
US-7598291-B2 Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin NIMNI MARCEL 2009-10-06 US disclosed
US-6576271-B2 Using plant extract BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2003-06-10 US disclosed
EP-1137429-A2 BIOFLAVONOIDS, ANTHOCYANINS AND PHENOLIC COMPOUNDS FROM CHERRIES FOR INHIBITING INFLAMMATION MICHIGAN STATE UNIVERSITY (US) 2001-10-04 EP disclosed
US-20010020009-A1 Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2001-09-06 US disclosed
US-20010002407-A1 Method for inhibiting cyclooxygenase and inflammation using cyanidin BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2001-05-31 US disclosed
US-6194469-B1 INHIBITING CYCLOOXYGENASE OR PROSTOGLANDIN H SYNTHASE ENZYMES BY PROVIDING AN ANTHOCYANIN ISOLATED FROM CHERRY FRUIT SELECTED FROM CYANIDIN-3-GLUCOSYLRUTINOSIDE, CYANIDIN-3-RUTINOSIDE OR CYANIDIN-3-GLUCOSIDE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERISTY 2001-02-27 US disclosed
WO-2000033824-A2 BIOFLAVONOIDS, ANTHOCYANINS AND PHENOLIC COMPOUNDS FROM CHERRIES FOR INHIBITING INFLAMMATION MICHIGAN STATE UNIVERSITY (US) 2000-06-15 WO disclosed
WO-2000033667-A2 BIOFLAVONOIDS, ANTHOCYANINS AND PHENOL COMPOUNDS FROM CHERRIES AS ANTIOXIDANTS MICHIGAN STATE UNIVERSITY (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060045926-A1 Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin COL1A1, COL14A1, COL2A1 PPARG 83/4885MAPT 3935/4885POLB 1108/4885
US-20100160244-A1 METHODS AND COMPOSITIONS FOR ENHANCING COLLAGEN, PROTEOGLYCAN, AND GLUTATHIONE SYNTHESIS IN THE SKIN CUTA, COL14A1, COL2A1 PPARG 329/4885MAPT 2821/4885POLB 1344/4885
US-20090053290-A1 TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN LRAT, LTA, COLGALT1 PPARG 367/4885MAPT 373/4885POLB 3696/4885
US-20060067959-A1 Compositions and methods for treatment of solar damage AAAS, LRRK2, CSTB PPARG 4278/4885MAPT 119/4885POLB 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.